SWOG clinical trial number
SWOG-8955

Treatment of Stage D, Hormone Refractory Carcinoma of the Prostate with 5/Fluorouracil and Roferon-A®, Phase II

Closed
Phase
Accrual
58%
Published
Abbreviated Title
Treatment of Stage D, Hormone Refractory Carcinoma of the Prostate with 5/Fluorouracil and Roferon-A®, Phase II
Activated
06/15/1992
Closed
11/01/1993

Research committees

Genitourinary Cancer

Publication Information Expand/Collapse

1996

Treatment of stage D2 hormone refractory carcinoma of the prostate with 5-fluorouracil and roferon-A: A Southwest Oncology Group study.

ME Marshall;M Wolf;M O'Rourke;TC Barnett;ED Crawford Cancer Biotherapy & Radiopharmaceuticals 11(2):119-123

1994

Effects of continued androgen-deprivation therapy and other prognostic factors on response and survival in phase II chemotherapy trials for hormone-refractory prostate cancer: A Southwest Oncology Group report.

M Hussain;M Wolf;E Marshall;ED Crawford;M Eisenberger Journal of Clinical Oncology 12(9):1868-1875

Other Clinical Trials

SWOG Clinical Trial Number
S2427

Single Arm Phase II Study of Bladder Preservation with Immunoradiotherapy after a Clinically Meaningful Response to Neoadjuvant Therapy in Patients with Muscle Invasive Bladder Cancer (BRIGHT)
Research Committee(s)
Genitourinary Cancer
Activated
09/04/2025
Accrual
1%
Open
Phase
SWOG Clinical Trial Number
CCTG-PR26

A Randomized Phase III Clinical Trial for the Addition of Docetaxel to Androgen Receptor Pathway Inhibitors in Patients with Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response (TRIPLE-SWITCH)
Research Committee(s)
Genitourinary Cancer
Activated
01/30/2025
Open
Phase
SWOG Clinical Trial Number
S2312

A Phase III Study of Cabazitaxel with or without Carboplatin in Patients with metastatic castrate-resistant prostate cancer (mCRPC), Stratified by Aggressive Variant Signature
Research Committee(s)
Genitourinary Cancer
Activated
09/03/2024
Accrual
7%
Open
Phase